Rani Therapeutics Holdings (RANI) Operating Expenses (2020 - 2026)

Rani Therapeutics Holdings' Operating Expenses history runs 7 years deep, the most recent figure standing at $10.0 million for Q1 2026.

• On a quarterly basis, Operating Expenses fell 17.55% year-over-year to $10.0 million in Q1 2026; TTM through Mar 2026 was $37.8 million, a 27.98% decrease from a year earlier, with the FY2025 full-year figure at $39.9 million, down 26.5% from the prior year.
• Operating Expenses climbed to $10.0 million in Q1 2026 per RANI's latest filing, from $10.0 million in the prior quarter.
• Across five years, Operating Expenses topped out at $18.3 million in Q2 2023 and bottomed at $7.3 million in Q3 2025.
• The 5-year median for Operating Expenses is $13.8 million (2022), against an average of $13.8 million.
• Biggest YoY gain for Operating Expenses was 131.44% in 2022; the steepest drop was 41.18% in 2022.
• Year by year, Operating Expenses stood at $17.5 million in 2022, then fell by 23.16% to $13.4 million in 2023, then increased by 19.0% to $16.0 million in 2024, then sank by 37.47% to $10.0 million in 2025, then gained by 0.51% to $10.0 million in 2026.
• Per Business Quant, the three latest RANI Operating Expenses figures stand at $10.0 million (Q1 2026), $10.0 million (Q4 2025), and $7.3 million (Q3 2025).